platoseedplatoseed
We are developing a drug to burn calories and increase metabolism…
We are developing a drug to increase metabolism and burn calories without exercise. Obesity and type 2 diabetes have reached epidemic proportions. There are 2.2B overweight people and 500M people with type 2 diabetes worldwide, and these numbers increase drastically every year. Existing drugs are not effective enough to reverse the trend. Our drug can solve this problem, because it addresses the root cause of metabolic disorders – the imbalance between caloric intake and expenditure. Our drug will target mitochondria – the powerhouse of the cell – to generate heat. This approach has been proven to fully reverse obesity and type 2 diabetes in animals. However, therapeutic application for humans was impossible, because mitochondrial heat production could only be induced by highly artificial methods with side effects. This changed after our recent breakthrough discovery of the protein that mitochondria naturally use to generate heat. We have developed a unique high-throughput drug discovery platform to identify compounds that selectively activate this target protein, without side effects. For decades people have wanted a drug that burns calories like exercise does. We are realizing this dream at Equator Therapeutics.
Equator Therapeutics is developing a first-in-class drug aimed at restoring thermogenesis by pharmacologically stimulating mitochondrial heat production to aid weight loss and treat metabolic disorders. The company emphasizes targeting mitochondrial pathways and utilizing high-throughput, electrophysiological assays to identify selective activators of thermogenesis. Long-term plans include expanding to other mitochondrial mechanisms.
The product approach centers on pharmacological activation of mitochondrial thermogenesis. Researchers identify proteins responsible for electrical currents in mitochondria and use high-throughput assays to screen compounds that induce those currents. The goal is to find activators that are selective and safe, with the potential to reverse metabolic disorders and eventually target additional mitochondrial therapeutic mechanisms.
Who it’s for: Researchers and developers in metabolic disorders, obesity treatment, and mitochondrial physiology; biotechnology/pharma partners and investors interested in first-in-class metabolic drugs.
team with academic and advisory board; publication history and focus on foundational research indicating early R&D stage
We create activating antibodies to treat diseases others can’t.
Altay develops disease-modifying therapies targeting transcription…
